辛波莫德,临床注释-2,变异和临床注释数据

辛波莫德

临床注释ID

1451231100

药物名称(英)

siponimod

变异单倍型

CYP2C9*1, CYP2C9*2, CYP2C9*3

基因

CYP2C9

证据级别

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Metabolism/PK

表现型类别

代谢/PK

分数

200.125

PMID计数

计数的证据

表现型

表现型(英)

最新日期

2021/3/24 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/1451231100

专业人口(英)

专业人口

临床等位基因

id	等位基因	注释文本
1325	*3	The CYP2C93 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C93 allele in combination with a normal, decreased or no function allele may have decreased metabolism and increased plasma concentrations of siponimod as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence metabolism of siponimod. This annotation only covers the pharmacokinetic relationship between CYP2C9 and siponimod and does not include evidence about clinical outcomes.
1324	*2	The CYP2C92 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C92 allele in combination with a decreased or no function allele may have decreased metabolism and increased plasma concentrations of siponimod as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence metabolism of siponimod. This annotation only covers the pharmacokinetic relationship between CYP2C9 and siponimod and does not include evidence about clinical outcomes.
1323	*1	The CYP2C91 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C91 allele in combination with another normal function allele may have increased metabolism and decreased plasma concentrations of siponimod as compared to patients carrying at least one decreased or no function alleles. Other genetic and clinical factors may also influence the metabolism of siponimod. This annotation only covers the pharmacokinetic relationship between CYP2C9 and siponimod and does not include evidence about clinical outcomes.

临床证据

id	证据的ID	总结
1253	1451230840	CYP2C9 3/3 + 2/2 are associated with decreased metabolism of siponimod as compared to CYP2C9 1/1.
1252	1451230861	CYP2C9 2/3 + 3/3 are associated with increased concentrations of siponimod in healthy individuals as compared to CYP2C9 1/1.
1251	PA166182738	Annotation of FDA Label for siponimod and CYP2C9
1250	PA166211021	Annotation of DPWG Guideline for siponimod and CYP2C9

临床病史

id	类型	评论
1476	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1475	Update	added guideline and label as evidence, updated text
1474	Create	Created

最新招商产品更多>>